Central nervous system neuroblastoma

1 trials 1 recruiting MedDRA PT
1 Registered trials
1 Recruiting
1 Unique sponsors
13 Unique IMPs
0 Commercial trials
Drug classes (ATC)
B Haematology (ATC B) 1
L Oncology (ATC L) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Alkylating agent 3 substances
Supportive / diluent 3 substances
Platinum compound 2 substances
Monoclonal antibody (chimeric) 1 substance
Anthracycline 1 substance
Topoisomerase II inhibitor 1 substance
Unknown / small molecule 1 substance
Vinca alkaloid 1 substance
Phase I/II: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase I/II

1 trial
  • Prinses Maxima Centrum voor Kinderoncologie B.V. Academic
    CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DINUTUXIMAB BETA; DOXORUBICIN HYDROCHLORIDE; ETOPOSIDE; GLUCOSE; HUMAN ALBUMIN SOLUTION; IFOSFAMIDE; SODIUM CHLORIDE; VINCRISTINE SULFATE; WATER FOR INJECTION
    2023-509673-22-00 7 countries 2024 n=39 Orphan
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Prinses Maxima Centrum voor Kinderoncologie B.V. Academic 1 Phase I/II 1
New trials by year
2024
1
← All indication landscapes